Clinical Trials Logo

Filter by:
NCT ID: NCT03866746 Completed - Clinical trials for Diabetic Macular Edema

Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema

MPL
Start date: May 8, 2017
Phase: Phase 4
Study type: Interventional

prospective study evaluating the impact of subthreshold micropulsed laser on the number of Aflibercept injections when used as an adjuvant therapy in eyes with diabetic macular edema.

NCT ID: NCT03809416 Recruiting - Atrophic Acne Scar Clinical Trials

Combined LASERs and PRP for Postacne Scars

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

This study evaluates a new combined technique using two different laser wavelengths and Platelets Rich Plasma (PRP) to treat post-atrophic acne scars. Within the available knowledge of laser-tissue interactions and effects of PRP on wound healing, we will explore the clinical effects of our new combination procedure on a histopathological and immunohistochemical basis for guiding future post acne scars clinical research.

NCT ID: NCT03709992 Recruiting - Quality of Life Clinical Trials

Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:

Start date: December 19, 2018
Phase: N/A
Study type: Interventional

This study will be conducted to compare the efficacy and safety of Trospium chloride versus Tamsulosin for treatment of ureteral stent related symptoms.

NCT ID: NCT03704623 Recruiting - Ureteric Stone Clinical Trials

Parecoxib vs Paracetamol in the Treatment of Acute Renal Colic

Start date: January 15, 2019
Phase: N/A
Study type: Interventional

This study will be conducted to compare the efficacy and safety of Parecoxib versus Paracetamol for treatment of acute renal colic due to ureteric stones.

NCT ID: NCT03703869 Active, not recruiting - Diabetes Clinical Trials

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.

ATOS
Start date: March 6, 2018
Phase:
Study type: Observational

Primary Objective: Assess effectiveness of insulin glargine (U300) in achieving glycemic goal measured by hemoglobin A1c (HbA1c). Secondary Objectives: - Assess effectiveness in achieving glycemic goal measured by HbA1c; - Assess effectiveness on change in HbA1c, fasting plasma glucose (FPG) and self-monitored plasma glucose (SMPG) ; - Assess requirement for intensification of therapy by additional antidiabetics. - Assess incidence of hypoglycemia; - Assess other safety endpoints: adverse events (AEs), serious adverse events (SAEs); - Assess change in body weight.

NCT ID: NCT03665025 Not yet recruiting - Clinical trials for Implant Site Reaction

Immediate Implant Placement With Immediate Professionalization in Aesthetic Area

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Immediate implant placement with immediate professionalization in the maxillary esthetic zone using mixture of allograft and xenograft vs xenografts to augment the jumping gap

NCT ID: NCT03656965 Active, not recruiting - Clinical trials for Drug Use for Unapproved Schedule

EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug

Start date: May 1, 2018
Phase: Phase 3
Study type: Interventional

PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report: Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy. The chances of the local recurrence or metastasis are higher in the patients at same stage with positive PCR-DNA of EBV in Nasopharyngeal carcinoma after same treatment.(ref.) Antiviral drugs have been used to inhibit EBV replication and target viral DNA polymerase are Foscarnet and phosphonoacetic acid both interact directly with the pyrophosphate-binding site of the enzyme, where Acyclovir as antiviral drug act at two levels: as competitive alternative substrates, competing with GTP on the substrate-binding site, and as DNA chain terminators, by incorporating into the growing DNA chain and blocking its elongation due to their acyclic structure.

NCT ID: NCT03618147 Recruiting - Clinical trials for Primary Immune Deficiency Disorder

Primary Immunodeficiency in Kuwait

Start date: July 16, 2018
Phase:
Study type: Observational [Patient Registry]

- Background/Rationale: Epidemiological data about Primary Immunodeficiency Disorders (PIDD) in Kuwait is needed to better understand peculiarities and to compare them with other regions and ethnicity. - Study hypothesis: PIDD is relatively common in Kuwait compared to populations from different geographic areas. The distribution of PIDD in Kuwait is different from other geographic areas with more severe forms being more frequent. - Brief inclusion and exclusion criteria of study participants: PIDD patients presented at different clinics/hospital in Kuwait. Patients with secondary immunodeficiencies (drug induced, virus induced, and immunodeficiency associated with metabolic disorders... ect), will be excluded - Estimated sample size of the study: All patients who were registered in KNPIDR since 2004 will be included in the study along with the new patients who will be recruited during the study period. - Primary objectives: - Determine the prevalence and frequency of different PIDD in Kuwait - Identify clinical presentation patterns for PIDD in Kuwait - Identify natural history of PIDD in Kuwait - Help to asses epidemiology of PIDD in Kuwait - Determine particularities about PIDD affecting the population in Kuwait - Determine the health impact of PIDD in Kuwait - Development of strategies to improve the care and the quality of life of patients with PIDD

NCT ID: NCT03532737 Recruiting - Clinical trials for Locally Advanced Head and Neck Cancer

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Start date: October 7, 2018
Phase: Phase 2
Study type: Interventional

Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically. In the last 2 years, immune check points inhibitors (mainly Programmed Death (PD)-1 inhibitors) were approved for metastatic/recurrent HNC. The favorable toxicity profile and durable responses was the main benefit of these drugs along the scope of cancers they were approved for. Aim of the study and methods: This will be a phase II non-randomized trial to define safety and efficacy of combining the PD-1 inhibitor pembrolizumab given concomitantly with the usual standard of care chemoradiation/bioradiation for locally advanced non-nasopharyngeal HNC. Primary end point will be assessment of toxicity and tolerability while the secondary end points will be response rates (RR) and progression free survival (PFS)

NCT ID: NCT03484065 Recruiting - Clinical trials for Afibrinogenemia, Congenital

Quality of Life in Patients With Congenital Afibrinogenemia

QualyAFIB
Start date: June 2016
Phase:
Study type: Observational

The aim of this observational study is to evaluate the quality of life in patients with congenital afibrinogenemia using the Haemo-QoL SF for kids and the Haem-A-QoL for adult patients.